Regulatory Background
On March 17, 2025, the National Medical Products Administration (NMPA) officially released the "Appendix for Sterile Products (Draft for Comments)." This is the first systematic revision since the initial version of the sterile drug production specification was issued 14 years ago in 2011. Behind this revision lies China's strategic plan to deeply integrate its drug regulation into the international system: In 2023, the NMPA passed the formal applicant assessment for PIC/S (Pharmaceutical Inspection Co-operation Scheme) with high standards. This revision fully aligns with international standards—not only comprehensively converging with the technical requirements of the updated "EU GMP Annex 1: Manufacture of Sterile Medicinal Products" (2022) but also echoing the cutting-edge regulatory requirements for sterile drug production from PIC/S member states.
The new appendix, with "Compliance by Design" as its core logic, systematically outlines upgraded requirements for 11 major modules, including facilities, processes, and sterilization methods. Particularly in risk control, it adds refined management indicators for the entire sterile production chain. The section on Sterilizing Filtration fully incorporates the EU's validation system for sterilizing filtration processes (covering integrity testing, redundant filtration, etc.), filling a gap in domestic technical specifications. This change demonstrates China's pharmaceutical industry's determination to align with international best practices and lays a technical standard foundation for the NMPA's eventual accession to PIC/S.
Table 1. Comparison of Updates in the Appendix for Sterile Products
Highlights of Regulatory Upgrades: 2025 New Rules vs. 2011 Version
More Scientific System Design
• Added: Filter material must be verified for compatibility with the drug solution (Articles 179, 181).
• Tightened: The layout of the sterilizing filtration system must be combined with microbial load monitoring (Article 180).
• Microbial Monitoring: For redundant systems, microbial load sampling is required before the first filter (Article 193).
• Upgraded: Validation of filtration parameters requires real-time recording and deviation investigation (Articles 185, 186).
Full-Chain Control of Integrity Testing
• Key Link: Post-sterilization, pre-use integrity testing (PUPSIT) for filters (Article 187).
• Exception Management: For scenarios with trace amounts of drug solution, a risk assessment-based alternative is permitted (Supplement to Article 187).
• Dual-Insurance Strategy: Integrity testing requirements for filters under different sequential filtration methods (Articles 191, 192).
Note: Any test failure should be documented and investigated.
Note: Any test failure should be documented and investigated. Performing the post-sterilization test on F1 before use carries a lower risk and is less likely to compromise downstream sterility.
Refined Management of Usage Duration
• Time Monitoring: The maximum single use is limited to 1 day; multi-batch production requires strict approval (Article 194).
• Mandatory Validation: The maximum usage time for the filter must be independently validated for each product (Article 195).
Upgraded Risk Control
• Integration into CCS: All filtration management must be incorporated into the company's Contamination Control Strategy (CCS) (Article 180).
• Scenario Coverage: Sterilization and testing are both required as a dual guarantee for lyophilizer sealing filters (Article 128).
Summary
The 2025 NMPA Appendix for Sterile Products strengthens the requirements for sterilizing filtration: It recommends implementing a redundant filtration system, promoting PUPSIT testing, building a validation system covering real-time parameter monitoring, compatibility, microbial load control, and filtration duration, and deeply integrating it into the CCS framework. The new regulations strengthen dynamic control in Grade A areas, requiring companies to reconstruct their process validation platforms and establish supply chain quality linkage mechanisms. As a professional filtration technology partner, we provide full lifecycle validation services for filters and strategic compliance consulting to empower companies to accurately meet the new regulatory requirements.